- Home
- IFRX vs TCBS Comparison
IFRX vs TCBS Comparison
Compare IFRX & TCBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- TCBS
- Stock Information
- Founded
- IFRX 2007
- TCBS 1934
- Country
- IFRX Germany
- TCBS United States
- Employees
- IFRX N/A
- TCBS N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- TCBS Banks
- Sector
- IFRX Health Care
- TCBS Finance
- Exchange
- IFRX Nasdaq
- TCBS Nasdaq
- Market Cap
- IFRX 53.5M
- TCBS 48.7M
- IPO Year
- IFRX 2017
- TCBS N/A
- Fundamental
- Price
- IFRX $1.60
- TCBS $16.29
- Analyst Decision
- IFRX Strong Buy
- TCBS
- Analyst Count
- IFRX 4
- TCBS 0
- Target Price
- IFRX $7.75
- TCBS N/A
- AVG Volume (30 Days)
- IFRX 577.2K
- TCBS 2.9K
- Earning Date
- IFRX 08-07-2025
- TCBS 08-01-2025
- Dividend Yield
- IFRX N/A
- TCBS 0.98%
- EPS Growth
- IFRX N/A
- TCBS N/A
- EPS
- IFRX N/A
- TCBS 0.80
- Revenue
- IFRX $191,224.00
- TCBS $14,831,000.00
- Revenue This Year
- IFRX N/A
- TCBS N/A
- Revenue Next Year
- IFRX $1,336.36
- TCBS N/A
- P/E Ratio
- IFRX N/A
- TCBS $20.37
- Revenue Growth
- IFRX 54.36
- TCBS 51.57
- 52 Week Low
- IFRX $0.71
- TCBS $14.25
- 52 Week High
- IFRX $2.82
- TCBS $19.40
- Technical
- Relative Strength Index (RSI)
- IFRX 89.35
- TCBS 60.02
- Support Level
- IFRX $0.82
- TCBS $15.87
- Resistance Level
- IFRX $0.96
- TCBS $16.30
- Average True Range (ATR)
- IFRX 0.11
- TCBS 0.08
- MACD
- IFRX 0.06
- TCBS 0.04
- Stochastic Oscillator
- IFRX 100.00
- TCBS 100.00
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.